Cambria Investment Management L.P. Acquires 30,156 Shares of Pfizer Inc. $PFE

Cambria Investment Management L.P. raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 8.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 397,747 shares of the biopharmaceutical company’s stock after buying an additional 30,156 shares during the quarter. Cambria Investment Management L.P.’s holdings in Pfizer were worth $10,135,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Grey Fox Wealth Advisors LLC purchased a new position in shares of Pfizer during the third quarter worth about $29,000. Howard Hughes Medical Institute bought a new position in shares of Pfizer in the second quarter worth approximately $30,000. Darwin Wealth Management LLC purchased a new stake in Pfizer in the second quarter valued at approximately $32,000. Evelyn Partners Asset Management Ltd bought a new stake in Pfizer during the second quarter valued at approximately $33,000. Finally, True Wealth Design LLC lifted its position in Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 974 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on PFE shares. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a research report on Thursday, February 12th. Bank of America reduced their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. TD Cowen restated a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Finally, Citigroup started coverage on Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average price target of $28.14.

Pfizer Price Performance

PFE opened at $27.33 on Thursday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The stock’s 50 day simple moving average is $26.61 and its 200 day simple moving average is $25.57. The firm has a market cap of $155.38 billion, a price-to-earnings ratio of 20.09 and a beta of 0.47. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.94.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.63 earnings per share. As a group, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Phase‑2 win for atirmociclib: Pfizer reported positive topline results from the randomized FOURLIGHT‑1 study showing its next‑generation CDK4 inhibitor plus fulvestrant met the primary endpoint and reduced risk of progression or death (~40%). The result strengthens Pfizer’s oncology pipeline and positions atirmociclib as a potential successor/competitive option to existing CDK4/6 therapies. Pfizer Announces Positive Topline Phase 2 Results for Atirmociclib
• Positive Sentiment: Analyst upgrade/price‑target raise: HSBC raised its price target on PFE to $32 and maintained a Buy rating, giving investors an incremental valuation tailwind and signaling analyst confidence in Pfizer’s medium‑term outlook. HSBC Raises Price Target on Pfizer
• Neutral Sentiment: Early liver program progress: Pfizer advanced a Phase‑1 study of PF‑07328948 (liver indication), an early readout that modestly adds breadth to the pipeline but is unlikely to drive material near‑term revenue given its very early stage. Pfizer Advances Early PF-07328948 Liver Study
• Neutral Sentiment: Market/commentary noise: Media/analyst chatter (including TV commentary and bullish opinion pieces) is drawing attention to Pfizer’s broad pipeline and long‑term potential, but these are sentiment drivers rather than new clinical or commercial facts. Expect short‑term volatility around headlines. Jim Cramer Notes Pfizer Has “Got a Lot of Stuff in the Pipeline”
• Negative Sentiment: Study termination in melanoma: Pfizer ended a Phase‑1 study of PF‑08046031 in early‑stage melanoma, trimming one oncology program. While not expected to be material to top‑line forecasts, it marginally reduces pipeline optionality and is a near‑term negative datapoint for investors focused on oncology depth. Pfizer Ends Early-Stage Melanoma Study

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.